CADL - Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
CADL - Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.